Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study

Abstract

Background Combined radiochemotherapy followed by maintenance chemotherapy with cisplatin, lomustine and vincristine within the NOA-07 study resulted in considerable short-term toxicity in adult medulloblastoma patients. Here we investigated the long-term impact of this treatment, focusing on neurocognitive functioning and health-related quality of life (HRQoL). Methods Neurocognitive functioning and HRQoL scores over time were determined, and differences between the posttreatment and follow-up assessments were calculated up to 18 months for neurocognition and 60 months for HRQoL. Results 28/30 patients were analyzed. The three preselected HRQoL scales (role, social and cognitive functioning) showed improved scores, to a clinically relevant extent (≥ 10 points), compared to post-treatment levels up to 30 months, but decreased afterwards. Z-scores for verbal working memory were worse during follow-up compared to post-treatment scores and remained impaired during 18 months follow-up (i.e. z-score below − 1 standard deviation). Attention was impaired post-treatment, and remained impaired to a clinically relevant extent during follow-up. Coordination/processing speed and lexical verbal fluency improved compared to post-treatment scores, and remained within the normal range thereafter. Other tests of verbal fluency were stable over time, with z-scores within the normal range. Conclusions This long-term follow-up study showed that the NOA-07 treatment regimen was not associated with a deterioration in HRQoL in the post-treatment period. Verbal working memory deteriorated, while other neurocognitive domains did not seem to be impacted negatively by the treatment.

Real Life Data on Patient-Reported Outcomes and Neuro-Cognitive Functioning of Lung Cancer Patients: The PRO-Long Study

“…The latter is commonly applied to HRQoL by defining MCIDs, which are widely accepted and recommended, with a 10 point change from baseline being accepted as clinically relevant (39). Similarly, in line with previous research on NCF, MCID in NCF tests was set at one standard deviation difference between baseline and each subsequent time point (40)(41)(42)(43).…”

How we treat medulloblastoma in adults

“…Neurocognitive deficits may also occur, mostly consisting of impaired attention, visual perception and verbal fluency. 1 Medulloblastomas have a propensity to disseminate within the subarachnoid space and, less frequently, to extraneural locations, e.g. the lymph nodes, bone marrow, skeleton, lung and liver, which may cause symptoms.…”

Toxicity Reduction after Craniospinal Irradiation via Helical Tomotherapy in Patients with Medulloblastoma: A Unicentric Retrospective Analysis

“…CSI dose reduction from 36 to 23.4 Gy did not decrease the irradiation’s effectiveness with a significant reduction in toxicity [ 57 , 58 , 59 ]. Therefore, in EORTC 1634-BTG (NOA-23) study, personalized risk-adapted therapy in adult medulloblastoma patients (>18 years old) with CSI with 23.4 Gy is currently under investigation [ 60 ].…”